Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 29, 2026
Why Is AST SpaceMobile (ASTS) Stock Down -13% Today?

Why Is AST SpaceMobile (ASTS) Stock Down -13% Today?

Key Takeaways

  • ASTS is declining approximately 13% in premarket trading on May 29, 2026, sliding from a prior close of $129.60 to roughly $112.75
  • The selloff follows a period of intense momentum and appears driven by a combination of valuation concerns, analyst skepticism, and dilution fears tied to the company's ongoing capital-raise strategy
  • Analysts have repeatedly flagged ASTS as potentially overvalued, with at least one firm rating the stock a "sector underperform" and calling its price "irrational" relative to projected free cash flow timelines
  • The company's Q1 2026 results missed estimates earlier this month, even as management reaffirmed full-year revenue guidance of $150M–$200M
  • Broader market participants are weighing the pace of satellite deployment, competitive pressure from SpaceX's direct-to-cell ambitions, and rising capital expenditure requirements
  • Traders are closely watching upcoming satellite launch milestones, Q2 earnings guidance, and any new capital-raise disclosures

Opening Summary

AST SpaceMobile, Inc. (ASTS) is a Texas-based satellite broadband company developing a space-based cellular network capable of delivering 4G/5G connectivity directly to standard smartphones — without requiring specialized hardware. Shares are trading down approximately 13% in Friday's premarket session on May 29, 2026, falling to roughly $112.75 from the prior session's closing price of $129.60. The sharp move erases a portion of the strong recent run that carried ASTS to all-time highs, with markets citing a convergence of valuation pressure, analyst caution, and dilution-linked selling as the primary forces behind today's decline.

Valuation Concerns and Analyst Pressure

ASTS has attracted persistent skepticism from Wall Street analysts even as the stock surged to record highs in recent weeks. Scotiabank analyst Andres Coello has publicly called the stock's valuation "irrational," arguing that even if AST SpaceMobile executes its full satellite deployment roadmap, the capital spending required will prevent the company from generating positive free cash flow until 2028 or 2029 at the earliest. Coello's analysis pointed to slow customer adoption in the U.S. and Japan, modest pricing power, and direct competition from SpaceX's expanding direct-to-cell infrastructure as key headwinds. When high-growth, high-momentum stocks reach elevated valuations without near-term profitability, a single shift in sentiment or market-wide risk appetite can trigger outsized pullbacks — and that dynamic appears to be at play today.

Earnings Miss and Capital Structure Concerns

ASTS reported Q1 2026 revenue of approximately $14.7 million — well below consensus estimates — though management reaffirmed its full-year 2026 revenue target of $150 million to $200 million and noted a growing backlog. The earnings shortfall raised questions about the pace of commercial service ramp-up relative to the company's aggressive spending profile. Adding to investor anxiety, the company has undertaken multiple capital raises in recent months — including a $1 billion convertible senior notes offering in February 2026 — which resulted in new share issuances and dilution concerns each time. Convertible note structures also tend to generate hedge-related short selling in the underlying stock, amplifying downward price pressure during periods of market stress.

Satellite Deployment and Competitive Risks

The technical execution of ASTS's satellite deployment program remains a central risk. A Blue Origin launch failure in April 2026 deposited a BlueBird satellite into an incorrect orbit, compounding schedule delays and sending shares down 15% in a single session. While regulatory approvals from the FCC have provided some relief, investors remain focused on whether the company can meet its 2026 target of approximately 45 satellites in orbit ahead of the next batch launch scheduled for mid-June. Competitive pressure from SpaceX, which locked in a $17 billion spectrum deal with EchoStar to bolster its direct-to-cell capabilities, continues to weigh on long-term market share assumptions for ASTS.

Market Context and Trading Activity

Today's premarket decline in ASTS comes after the stock touched what appears to be an all-time high near $129.60 in the most recent session, a level that naturally invites profit-taking by traders managing risk at technical extremes. Volume in premarket trading is already running well above average, reflecting elevated retail and institutional activity. The broader satellite and space sector has shown heightened volatility throughout 2026, and peer names in the satellite communications space have also experienced sharp swings tied to launch outcomes and financing disclosures. When a momentum stock trades at all-time highs and faces a cluster of near-term uncertainties, the path of least resistance can quickly shift lower, particularly in thin premarket conditions.

Trending AI Robots

For traders navigating volatile sessions like today's move in ASTS, Tickeron's platform offers a powerful set of automated trading tools. Tickeron operates hundreds of AI-powered trading bots covering thousands of tickers across multiple asset classes, but only the highest-performing bots under current market conditions are spotlighted in its curated Trending AI Robots section. These robots vary widely by strategy, timeframe, risk parameters, performance metrics, and the specific symbols they trade, giving users flexibility to match bots to their own investment style. Whether you're focused on momentum plays, mean reversion, or swing trading, the Trending AI Robots page provides a regularly updated snapshot of which automated strategies are performing best right now — a useful starting point for traders looking to bring discipline and data to fast-moving markets.

What Comes Next for ASTS

Looking ahead, the next major catalyst for ASTS will be the mid-June BlueBird satellite launch, which management has flagged as a critical milestone toward meeting its 2026 deployment targets. Any delay, launch anomaly, or orbit insertion failure could trigger another sharp selloff, while a successful deployment could reinvigorate bullish sentiment. Investors will also be watching Q2 2026 earnings closely, particularly for signs that commercial revenue is accelerating toward the full-year $150M–$200M guidance range. Analyst coverage remains mixed, with some firms maintaining buy ratings while others carry sell or underperform designations — a split that reflects genuine uncertainty about the timeline to profitability. Rakuten's sale of $271 million worth of ASTS shares in recent months also warrants attention as a signal from a key strategic partner. The risk/reward calculus for ASTS will depend heavily on operational execution over the next two quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Related Ticker: ASTS

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


ASTS sees MACD Histogram crosses below signal line

ASTS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 01, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 43 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ASTS as a result. In 69 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

ASTS moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASTS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for ASTS entered a downward trend on September 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASTS advanced for three days, in 235 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. ASTS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.653) is normal, around the industry mean (5.894). ASTS's P/E Ratio (1113.640) is considerably higher than the industry average of (107.419). ASTS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.778). Dividend Yield (0.000) settles around the average of (0.006) among similar stocks. ASTS's P/S Ratio (147.059) is very high in comparison to the industry average of (11.937).

Notable companies

The most notable companies in this group are Cisco Systems (NASDAQ:CSCO), Hewlett Packard Enterprise Company (NYSE:HPE), Lumentum Holdings (NASDAQ:LITE), Nokia Corp (NYSE:NOK), Ciena Corp (NYSE:CIEN), Ericsson (NASDAQ:ERIC).

Industry description

The Telecommunications Equipment industry produces voice and data communications equipment, which includes fiber optic delivery products, digital signal processors, high-speed voice, data and video delivery. Additionally, satellite systems, global positioning systems, wireless data systems, personal communications equipment, telephone handsets and payload equipment for satellites also fall into this category. Apple Inc., QUALCOMM Incorporated and Nokia are major global players in this segment.

Market Cap

The average market capitalization across the Telecommunications Equipment Industry is 19.96B. The market cap for tickers in the group ranges from 3.88K to 420.83B. CSCO holds the highest valuation in this group at 420.83B. The lowest valued company is DZSI at 3.88K.

High and low price notable news

The average weekly price growth across all stocks in the Telecommunications Equipment Industry was 2%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 6%. INSG experienced the highest price growth at 28%, while CLRO experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Telecommunications Equipment Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was -17% and the average quarterly volume growth was -57%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 56
Price Growth Rating: 52
SMR Rating: 74
Profit Risk Rating: 75
Seasonality Score: 3 (-100 ... +100)
View a ticker or compare two or three
ASTS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a blank check company, which has formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization

Industry TelecommunicationsEquipment

Industry
N/A
Address
2901 Enterprise Lane
Phone
+1 432 276-3966
Employees
1126
Web
https://www.ast-science.com
Interact to see
Advertisement
I've been following ANTX, a biopharmaceutical company based in Menlo Park, California, that develops novel small molecule therapeutics from its proprietary boron chemistry platform. The focus is on underserved areas like infectious diseases, with the lead candidate epetraborole advancing in Phase 3 trials for non-tuberculous mycobacterial (NTM) lung disease and acute melioidosis. The pipeline also includes AN2-502998 for chronic Chagas disease in preclinical stages, along with programs in oncology.
Tilly's, Inc. (TLYS) operates as a specialty retailer specializing in casual apparel, footwear, accessories, and hardgoods aimed at young men, women, boys, and girls. The company focuses on branded fashion inspired by action sports, surf, and skate culture, offering products like tops, bottoms, swimwear, backpacks, hats, and sunglasses from well-known brands such as Vans and Hurley. With approximately 223 stores in malls and lifestyle centers, complemented by e-commerce through www.tillys.com, Tilly's effectively combines physical and digital sales channels.
Aemetis, Inc. (AMTX) is a renewable natural gas and renewable fuels company focused on developing and commercializing low- and negative-carbon intensity products that replace petroleum-based fuels. The company operates through segments including California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. Its core business model centers on converting agricultural waste—such as dairy manure into biogas and corn/wood waste into ethanol—into high-value biofuels like renewable natural gas (RNG), ethanol, biodiesel, and sustainable aviation fuel precursors.
Silvaco Group, Inc. (SVCO) provides technology computer-aided design (TCAD) software, electronic design automation (EDA) software, and semiconductor intellectual property (SIP) solutions. The company helps semiconductor and photonics firms design, simulate, and optimize processes from atomic-level modeling to complex system-on-chip (SoC) development. Its business centers on licensing software tools and IP blocks, along with engineering services, targeting high-growth areas like AI, power devices, automotive, foundries, and 5G/6G mobile.
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
APTV shares are tumbling approximately 14% in premarket trading on April 1, 2026, representing one of the sharpest single-session losses in the stock's recent history. The primary catalyst is Aptiv's Board of Directors formally approving the long-anticipated spin-off of its Electrical Distribution Systems (EDS) business, now named Versigent, combined with the announcement of a $1.6 billion private offering of senior notes tied to the transaction.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
RH shares are down approximately 17% in premarket trading on April 1, 2026, after closing the previous session at $139.82, with the stock indicated near $115.76 — a decline of roughly $24 per share. The primary catalyst is a significant Q4 fiscal year 2025 earnings miss, with adjusted EPS of $1.53 coming in well below the Wall Street consensus of $2.22 — a 31% negative surprise.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ORIC Pharmaceuticals shares are down approximately 21% in premarket trading on April 1, 2026, from a prior session close of approximately $12.19, placing the premarket price near $9.63. The primary catalyst is the after-market release of Phase 1b dose optimization data for rinzimetostat (ORIC-944) on March 31, alongside the selection of 400 mg once daily as the recommended Phase 3 dose for the Himalayas-1 registrational trial.
Shares of Target Hospitality Corp. (Nasdaq: TH) surged approximately 38% during Wednesday's trading session, climbing from a prior close of $9.28 to approximately $12.81. The primary catalyst is the company's announcement of a landmark multi-year lease and services agreement worth over $550 million with a top-five global hyperscaler to build and operate a data center workforce community in North Texas.
Shares of Turning Point Brands (TPB) are falling sharply intraday on April 1, 2026, shedding approximately 15% from their prior session close of roughly $87.41, placing the stock near $74.30. The primary catalyst is broad investor risk-off selling tied to mounting trade-policy uncertainty ahead of President Trump's sweeping tariff announcements scheduled for April 2 — a day the administration has branded "Liberation Day".
Shares of Philip Morris International fell approximately 8% during intraday trading on April 1, 2026, dropping from a prior close of $165.34 to around $152.11. A sharp, broad-based market selloff — amplified by renewed trade policy tensions — is acting as the primary macro catalyst behind the decline.
WDC shares surged approximately +10% in Wednesday's session, advancing to approximately $296–$297 from a prior close near $269.82 on March 31, 2026. The primary catalyst is a major analyst upgrade: Bernstein raised its rating on Western Digital from Market Perform to Outperform and dramatically doubled its price target to $340 from $170.
I've been following CG Oncology, Inc. (CGON), a late-stage clinical biopharmaceutical company dedicated to developing and commercializing cretostimogene grenadenorepvec. This investigational oncolytic immunotherapy aims to serve as a bladder-sparing therapeutic for patients with non-muscle invasive bladder cancer (NMIBC). The company's focus remains on pushing this intravesical therapy through Phase 3 trials to address high unmet needs in BCG-unresponsive and intermediate-risk NMIBC, where treatments like BCG frequently fall short. In the broader biotech landscape, CG Oncology stands out with cretostimogene's encouraging durability and tolerability, which could position it as a foundational therapy. From what I see, these solid fundamentals—bolstered by strong clinical data and regulatory steps—have directly supported the recent stock price gains amid positive trial developments.